INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
05/12/2025
Voltar para busca
Dado oficial do USPTO
IRIS PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
82
Atualização mais recente
06/12/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 35, 42
Data de depósito
09/04/2015
Data de registro
26/12/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/10/2024
Última transação
06/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
LA GAUDE, FR
Examinador
HAYES,GINA CLARK
Localização atual
Historical data usage
Descrição da marca
The mark consists of a logo, itself consisting of several geometric shapes; the middle of the logo is superimposed over one of the angles of each other geometric shape and is represented by a pink triangle shaded from the lightest at the top to the darkest at the bottom; The top left shape consists of five angles including a right angle on the upper left side and is in turquoise blue shaded from the darkest at the top left to the lightest at the bottom right; the top right shape consists of five angles including a rounded angle on the upper right side and is in orange shaded from the darkest at the top right to the lightest at the bottom left; The lower shape is central and consists of five angles including a rounded angle on the lower left corner and a right angle on the lower right and is in blue shaded from the darkest in the right to the lightest on the left; The words "IRIS PHARMA" are written in grey to the right of the geometric logo described above; The word "IRIS" is written in stylized font in lower case letters; below the word "IRIS" is the word "PHARMA" in standard font in capital letters.
Titulares e representantes
Titulares
I. P. (pessoa física)
I. P. (pessoa física)
Representantes
Mary L. Grieco Olshan Frome Wolosky LLP
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of eye diseases; chemical preparations for ophthalmic use; diagnostic preparations for ophthalmic use; biological preparations for the treatment of ophthalmic and eye diseases; biomarking reagents for diagnosis for ophthalmic purposes; medicines for humans for the treatment of ophthalmic conditions; eye-washes; contact lens cleaning preparations
Classe 35
Marketing studies and research for business purposes for others in the pharmaceuticalparapharmaceutical and veterinary fields for ophthalmic purposes
Classe 42
Clinical trials for others in the field of pharmaceuticals for ophthalmic purposes; pre-clinical testing for others in the pharmaceuticalparapharmaceutical and veterinary fields for ophthalmic purposes; in-vitro testing services for others in the pharmaceuticalparapharmaceutical and veterinary fields for ophthalmic purposes; specialized scientific laboratory services in the pharmaceuticalparapharmaceutical and veterinary fields for ophthalmic purposes; scientific research and studies in the field of eye disease; medicalpharmacologicalbiological and chemistry studies and research; research and development of new medical devicespharmaceuticalveterinary and parapharmaceutical products for others; consulting in the medical and scientific research in the field of eye disease; biologicalchemical and pharmacological analysis of pharmaceutical and parapharmaceutical and veterinary products for eye purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
82 publicações encontradas
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
27/10/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
27/10/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
27/10/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
05/06/2025
RNWL
INTERNATIONAL REGISTRATION RENEWED
17/04/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
28/03/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
05/10/2024
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
05/10/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/05/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/05/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
31/10/2023
ES71
TEAS SECTION 71 RECEIVED
18/09/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
26/12/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
13/06/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/05/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/04/2018
FIMP
FINAL DISPOSITION PROCESSED
02/04/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/03/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
26/12/2017
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
19/11/2017
CHPB
POST PUBLICATION AMENDMENT - ENTERED
03/10/2017
APET
ASSIGNED TO PETITION STAFF
02/10/2017
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
07/09/2017
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
10/08/2017
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
21/07/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/07/2017
PUBO
PUBLISHED FOR OPPOSITION
11/07/2017
GPNX
NOTIFICATION PROCESSED BY IB
08/07/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/07/2017
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/07/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/06/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
21/06/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/06/2017
LOPR
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
06/06/2017
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
05/06/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/05/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/05/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
05/05/2017
ALIE
ASSIGNED TO LIE
05/05/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/05/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
05/05/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/05/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/05/2017
GNRT
NON-FINAL ACTION E-MAILED
05/05/2017
CNRT
NON-FINAL ACTION WRITTEN
05/05/2017
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
03/05/2017
PBSR
WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST
03/04/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/03/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/02/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/02/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/02/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/02/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
29/08/2016
GNRT
NON-FINAL ACTION E-MAILED
29/08/2016
CNRT
NON-FINAL ACTION WRITTEN
29/08/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/08/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/08/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/08/2016
RFNT
REFUSAL PROCESSED BY IB
01/04/2016
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
28/03/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/02/2016
GNRT
NON-FINAL ACTION E-MAILED
10/02/2016
CNRT
NON-FINAL ACTION WRITTEN
10/02/2016
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
10/02/2016
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
05/02/2016
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
22/01/2016
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
08/12/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/10/2015
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/10/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/10/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/10/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/10/2015
RFNT
REFUSAL PROCESSED BY IB
12/09/2015
MAFR
APPLICATION FILING RECEIPT MAILED
25/08/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/08/2015
RFRR
REFUSAL PROCESSED BY MPU
21/08/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/08/2015
CNRT
NON-FINAL ACTION WRITTEN
20/08/2015
DOCK
ASSIGNED TO EXAMINER
19/08/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/08/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/08/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IRIS PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.